Get started
AstraZeneca PLCAA

AstraZeneca PLC

73.79USDR
+0.95+1.30%
At close at Mar 28, 23:50 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options Bonds

AZN fundamentals

Key facts

Market capitalization‪229.22 B‬USD
Dividend yield (indicated)2.06%
Price to earnings Ratio (TTM)32.32
Basic EPS (TTM)2.27USD
Founded1992
Employees (FY)‪94.3 K‬
CEOPascal Soriot
Websiteastrazeneca.co.uk
About

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Ownership
‪‪3.10 B‬‬
Free Float shares
‪‪3.10 B‬‬ (99.98%)
Closely held shares
‪‪657.46 K‬‬ (0.02%)
Free Float shares
‪‪3.10 B‬‬ (99.98%)
Closely held shares
‪‪657.46 K‬‬ (0.02%)
Capital structure
Market cap
‪‪229.22 B‬‬
Debt
‪‪30.30 B‬‬
Minority interest
‪‪85.00 M‬‬
Cash & equivalents
‪‪5.65 B‬‬
Enterprise value
‪‪253.95 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪229.22 B‬‬
Price to earning ratio (P/E)
32.32x
Price to sales ratio (P/S)
4.21x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
32.32x
Price to sales ratio (P/S)
4.21x
Valuation ratios
‪0.00‬
‪1.30‬
‪2.60‬
‪3.90‬
‪5.20‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪10.00‬
‪20.00‬
‪30.00‬
‪40.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪7.5%‬
‪10.0%‬
‪12.5%‬
‪15.0%‬
‪17.5%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Oncology
Cardiovascular, Renal and Metabolism
Rare Disease
Respiratory and Immunology
Alliance
Other Medicines
Vaccines and Immune Therapies
Collaboration
By country
Period: 2024
United States
China
United Kingdom
Other
Other Rest of Europe
Japan
Germany
Other Asia, Africa and Australasia
Sweden
Other Americas

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 29, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
66.97%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
2.06%
Last payment
1.03
Last ex-date
Feb 21, 2025
Dividend history
‪2.0%‬
‪2.2%‬
‪2.4%‬
‪2.6%‬
‪2.8%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.40‬
‪0.80‬
‪1.20‬
‪1.60‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪20.00 B‬‬
‪‪40.00 B‬‬
‪‪60.00 B‬‬
‪‪80.00 B‬‬
Assets
Liabilities